Rybelsus (semaglutide) now available in tablet form in UK

Status
Not open for further replies.

Amity Island

Well-Known Member
Relationship to Diabetes
Type 1
Novo Nordisk has announced that Rybelsus® (semaglutide tablets), the world’s first and only oral GLP1-RA treatment for type 2 diabetes (T2D), is now available in the UK. After 15 years of research and innovation and investment from Novo Nordisk of approximately £1.8 million in clinical R&D, this new GLP-1 RA treatment can help people with T2D achieve their target blood sugar, with the additional benefit of weight loss, with a convenient once-daily tablet.


 
Status
Not open for further replies.
Back
Top